ThomasSim的个人主页 - 老虎社区

ThomasSim

ThomasSim

暂无个人介绍

IP属地：未知

38关注

6粉丝

0主题

0勋章

2021-06-11

$ArcLight Clean Transition Corp(ACTC)$today vote for merger, fly

2021-10-28

$Tiger Brokers(TIGR)$eehh.. i tot Tiger got HongKong License? In other words like not really impacted? Lol

2021-10-15

$Tiger Brokers(TIGR)$around 50-60% shorts for float. Gamma squeeze target.

2021-06-24

Nice

Comcast Says 'Pure Speculation' It's Mulling Bids for ViacomCBS or Roku

2021-07-15

Nice nice

3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street

2021-06-09

$ACTCProterra going to merge~https://www.google.com/amp/s/seekingalpha.com/amp/article/4432196-actc-a-very-popular-spac-soon-holds-a-vote-on-buying-proterra

2021-10-27

$Fiverr International Ltd.(FVRR)$hais

2021-07-01

Oh dear

Barclays says ZipRecruiter’s stock price can jump 20% amid U.S. labor supply and demand mismatch

2021-06-18

$Intel(INTC)$i thought should be factored in. Not new thing that apple wanna do their own chips

2021-07-07

Comment like and comment like and comment

抱歉，原内容已删除

2021-07-07

Nice nice nice, posting for tiger coins

抱歉，原内容已删除

2021-06-24

Nice

The ‘shelter in suburbia’ trade is about to reverse — and these stocks will suffer

2021-07-07

Nice nice nice nice nice. Tiger coins nice.

抱歉，原内容已删除

2021-06-24

$Tiger Brokers(TIGR)$zzzz pls up

2021-06-10

Proterra to the moon

2021-06-15

$ArcLight Clean Transition Corp(PTRA)$rubbish sia so weak, dump this shit

2021-08-15

PROTERRA

抱歉，原内容已删除

2021-07-09

Nice Man

抱歉，原内容已删除

2021-06-22

Nice

抱歉，原内容已删除

2021-06-16

$Intel(INTC)$whats holding you back intel

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3566283048885824,"uuid":"3566283048885824","gmtCreate":1603190857112,"gmtModify":1623247198676,"name":"ThomasSim","pinyin":"thomassim","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":38,"tweetSize":32,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"93.75%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.15%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":691282938,"gmtCreate":1640206448271,"gmtModify":1640206448397,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Ya sia, ok ah","listText":"Ya sia, ok ah","text":"Ya sia, ok ah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691282938","repostId":"2193927561","repostType":4,"repost":{"id":"2193927561","pubTimestamp":1640184600,"share":"https://www.laohu8.com/m/news/2193927561?lang=&edition=full","pubTime":"2021-12-22 22:50","market":"us","language":"en","title":"Philips receives FDA De Novo Clearance for IVC Filter Removal Laser Sheath - CavaClear - with Breakthrough Device Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2193927561","media":"GlobeNewswire","summary":"Philips IVC Filter Removal Laser Sheath – CavaClear – is intended to safely ablate tissue to remove ","content":"<ul>\n <li><i>Philips IVC Filter Removal Laser Sheath – CavaClear – is intended to safely ablate tissue to remove embedded IVC filters</i></li>\n <li><i>CavaClear is a first-in-class FDA-cleared solution for advanced IVC filter removal</i></li>\n <li><i>It is estimated that in the United States more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> million patients with IVC filters would benefit from filter removal to reduce the risk of long-term complications [1,2]</i></li>\n <li><i><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> independent and prospective clinical studies demonstrated that laser-assisted retrieval was 96-99.4% effective with a major adverse event rate of 0.7-2% [3,4]</i></li>\n</ul>\n<p><b>Amsterdam, the Netherlands –</b> <u>Royal Philips</u> (NYSE: PHG, AEX: PHIA), a global leader in health technology today announced the FDA has granted De Novo Clearance for Philips IVC Filter Removal Laser Sheath – CavaClear – to remove an IVC filter when previous methods of removal have failed. CavaClear is the first and only FDA-cleared solution for advanced IVC filter removal. Earlier in 2021, the FDA granted the device <u>Breakthrough Device Designation</u>. Laser has been clinically proven to provide a success rate over 99%, with low complication rates [3].</p>\n<p>IVC filters are used to treat patients with venous thromboembolism, in which blood clots form in the deep veins of the leg and groin, and can travel through the circulatory system. They are placed in the inferior vena cava to capture blood clots from moving to the lungs. However, research has shown that IVC filters may have long-term complications [5]. The filters can fracture and travel through the bloodstream to other parts of the body. Other identified long-term risks associated with IVC filters include lower limb deep vein thrombosis and IVC occlusion. The FDA recommends that implanting physicians consider removing retrievable IVC filters as soon as they are no longer indicated [2].</p>\n<p>Failure rates for IVC filter removal can be high and prior to CavaClear, limited options for removal existed if the filter became difficult to remove. Advanced retrieval tools and techniques are required if the IVC filter becomes embedded in the vasculature. Physicians previously had very few tools to remove the filter when complications occurred and until now there were no FDA-approved devices for this type of advanced removal.</p>\n<p>“Today is a historic day. With the approval of CavaClear, physicians now have a device specifically geared remove chronically embedded IVC filters,” said Kush R. Desai MD, FSIR, Associate Professor of Radiology, Surgery, and Medicine, and Director of Deep Venous Interventions at Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. “Backed by evidence, this technology can be applied to retrieve IVC filters that are no longer indicated, reducing potential clinical risk for patients and satisfying the FDA’s guidance to retrieve filters when they are no longer indicated.”</p>\n<p><b>Clinical research supports laser-assisted removal</b></p>\n<p><a href=\"https://laohu8.com/S/TWOA\">Two</a> independent and prospective clinical studies demonstrated that laser-assisted retrieval was 96-99.4% effective with a major adverse event rate of 0.7-2% [3,4]. Philips CavaClear uses circumferential tissue ablation that can aid in capturing the filter within seconds of laser activation, which can help increase physician efficiency during removal, and may help lower costs by reducing the number of retrieval attempts needed to remove an embedded filter. In addition, the simple and safe design is easy for physicians to integrate into their workflow.</p>\n<p>“With the FDA’s clearance of our IVC Filter Removal Laser Sheath – CavaClear – more than one million patients and their physicians now have access to a safe, effective and efficient option for advanced IVC filter removal,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “This clearance demonstrates the commitment of Philips to innovating procedures with physician collaboration to meet unmet needs that can have a critical impact on the lives of patients and their families.”</p>\n<p>[1] Philips internal market research data calculation.</p>\n<p>[2] <u>Health, C. for D. and R. Safety Communications - Removing Retrievable Inferior Vena Cava Filters: FDA Safety Communication. (2014)</u>.</p>\n<p>[3] Kuo, W. et al. Laser‐Assisted Removal of Embedded Vena Cava Filters: A First‐In‐Human Escalation Trial in 500 Patients Refractory to High‐Force Retrieval.&nbsp;Journal of the American Heart Association&nbsp;9:24, 1-9 (2020).</p>\n<p>[4] Desai, K. et al. Excimer Laser Sheath-Assisted Retrieval of “Closed-Cell” Design Inferior Vena Cava Filters. J Am Heart Assoc; 9: e017240 (2020).</p>\n<p>[5] Van Ha, T. G. Complications of inferior vena caval filters. <i>Semin. Interv. Radiol.</i> 23, 150–155 (2006).</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Philips receives FDA De Novo Clearance for IVC Filter Removal Laser Sheath - CavaClear - with Breakthrough Device Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhilips receives FDA De Novo Clearance for IVC Filter Removal Laser Sheath - CavaClear - with Breakthrough Device Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 22:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/philips-receives-fda-novo-clearance-140000021.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Philips IVC Filter Removal Laser Sheath – CavaClear – is intended to safely ablate tissue to remove embedded IVC filters\nCavaClear is a first-in-class FDA-cleared solution for advanced IVC filter ...</p>\n\n<a href=\"https://finance.yahoo.com/news/philips-receives-fda-novo-clearance-140000021.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4082":"医疗保健设备","PHG":"飞利浦"},"source_url":"https://finance.yahoo.com/news/philips-receives-fda-novo-clearance-140000021.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193927561","content_text":"Philips IVC Filter Removal Laser Sheath – CavaClear – is intended to safely ablate tissue to remove embedded IVC filters\nCavaClear is a first-in-class FDA-cleared solution for advanced IVC filter removal\nIt is estimated that in the United States more than one million patients with IVC filters would benefit from filter removal to reduce the risk of long-term complications [1,2]\nTwo independent and prospective clinical studies demonstrated that laser-assisted retrieval was 96-99.4% effective with a major adverse event rate of 0.7-2% [3,4]\n\nAmsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology today announced the FDA has granted De Novo Clearance for Philips IVC Filter Removal Laser Sheath – CavaClear – to remove an IVC filter when previous methods of removal have failed. CavaClear is the first and only FDA-cleared solution for advanced IVC filter removal. Earlier in 2021, the FDA granted the device Breakthrough Device Designation. Laser has been clinically proven to provide a success rate over 99%, with low complication rates [3].\nIVC filters are used to treat patients with venous thromboembolism, in which blood clots form in the deep veins of the leg and groin, and can travel through the circulatory system. They are placed in the inferior vena cava to capture blood clots from moving to the lungs. However, research has shown that IVC filters may have long-term complications [5]. The filters can fracture and travel through the bloodstream to other parts of the body. Other identified long-term risks associated with IVC filters include lower limb deep vein thrombosis and IVC occlusion. The FDA recommends that implanting physicians consider removing retrievable IVC filters as soon as they are no longer indicated [2].\nFailure rates for IVC filter removal can be high and prior to CavaClear, limited options for removal existed if the filter became difficult to remove. Advanced retrieval tools and techniques are required if the IVC filter becomes embedded in the vasculature. Physicians previously had very few tools to remove the filter when complications occurred and until now there were no FDA-approved devices for this type of advanced removal.\n“Today is a historic day. With the approval of CavaClear, physicians now have a device specifically geared remove chronically embedded IVC filters,” said Kush R. Desai MD, FSIR, Associate Professor of Radiology, Surgery, and Medicine, and Director of Deep Venous Interventions at Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. “Backed by evidence, this technology can be applied to retrieve IVC filters that are no longer indicated, reducing potential clinical risk for patients and satisfying the FDA’s guidance to retrieve filters when they are no longer indicated.”\nClinical research supports laser-assisted removal\nTwo independent and prospective clinical studies demonstrated that laser-assisted retrieval was 96-99.4% effective with a major adverse event rate of 0.7-2% [3,4]. Philips CavaClear uses circumferential tissue ablation that can aid in capturing the filter within seconds of laser activation, which can help increase physician efficiency during removal, and may help lower costs by reducing the number of retrieval attempts needed to remove an embedded filter. In addition, the simple and safe design is easy for physicians to integrate into their workflow.\n“With the FDA’s clearance of our IVC Filter Removal Laser Sheath – CavaClear – more than one million patients and their physicians now have access to a safe, effective and efficient option for advanced IVC filter removal,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “This clearance demonstrates the commitment of Philips to innovating procedures with physician collaboration to meet unmet needs that can have a critical impact on the lives of patients and their families.”\n[1] Philips internal market research data calculation.\n[2] Health, C. for D. and R. Safety Communications - Removing Retrievable Inferior Vena Cava Filters: FDA Safety Communication. (2014).\n[3] Kuo, W. et al. Laser‐Assisted Removal of Embedded Vena Cava Filters: A First‐In‐Human Escalation Trial in 500 Patients Refractory to High‐Force Retrieval. Journal of the American Heart Association 9:24, 1-9 (2020).\n[4] Desai, K. et al. Excimer Laser Sheath-Assisted Retrieval of “Closed-Cell” Design Inferior Vena Cava Filters. J Am Heart Assoc; 9: e017240 (2020).\n[5] Van Ha, T. G. Complications of inferior vena caval filters. Semin. Interv. Radiol. 23, 150–155 (2006).","news_type":1},"isVote":1,"tweetType":1,"viewCount":684,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854942514,"gmtCreate":1635414882300,"gmtModify":1635414965590,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Tiger has HongKong License. Legally compliance.","listText":"Tiger has HongKong License. Legally compliance.","text":"Tiger has HongKong License. Legally compliance.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854942514","repostId":"854954454","repostType":1,"repost":{"id":854954454,"gmtCreate":1635414280215,"gmtModify":1635414471718,"author":{"id":"3518983480179242","authorId":"3518983480179242","authorIdStr":"3518983480179242","name":"fincc","avatar":"https://static.tigerbbs.com/752def79475c77ddbeaceabf192b8c5d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3518983480179242"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>以个人信息安全为由头获取内地客户规模情况，以非法金融活动吹风，最终的命运是下架和清退。几乎是这个套路。","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>以个人信息安全为由头获取内地客户规模情况，以非法金融活动吹风，最终的命运是下架和清退。几乎是这个套路。","text":"$老虎证券(TIGR)$以个人信息安全为由头获取内地客户规模情况，以非法金融活动吹风，最终的命运是下架和清退。几乎是这个套路。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854954454","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854029178,"gmtCreate":1635411502561,"gmtModify":1635411685942,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>eehh.. i tot Tiger got HongKong License? In other words like not really impacted? Lol","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>eehh.. i tot Tiger got HongKong License? In other words like not really impacted? Lol","text":"$Tiger Brokers(TIGR)$eehh.. i tot Tiger got HongKong License? In other words like not really impacted? Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854029178","isVote":1,"tweetType":1,"viewCount":2255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852736071,"gmtCreate":1635301474432,"gmtModify":1635301508927,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FVRR\">$Fiverr International Ltd.(FVRR)$</a>hais","listText":"<a href=\"https://laohu8.com/S/FVRR\">$Fiverr International Ltd.(FVRR)$</a>hais","text":"$Fiverr International Ltd.(FVRR)$hais","images":[{"img":"https://static.tigerbbs.com/fbf74a8f4d8721100dbe1d28d827cf26","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/852736071","isVote":1,"tweetType":1,"viewCount":1508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":824877060,"gmtCreate":1634305910155,"gmtModify":1634306364271,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>around 50-60% shorts for float. Gamma squeeze target.","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>around 50-60% shorts for float. Gamma squeeze target.","text":"$Tiger Brokers(TIGR)$around 50-60% shorts for float. Gamma squeeze target.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/824877060","isVote":1,"tweetType":1,"viewCount":857,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824873198,"gmtCreate":1634305591012,"gmtModify":1634306083758,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>tigr shorts should be around 50-60% now.","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>tigr shorts should be around 50-60% now.","text":"$Tiger Brokers(TIGR)$tigr shorts should be around 50-60% now.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/824873198","isVote":1,"tweetType":1,"viewCount":624,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":830390036,"gmtCreate":1629007465625,"gmtModify":1631890295587,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"PROTERRA","listText":"PROTERRA","text":"PROTERRA","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/830390036","repostId":"1138531277","repostType":4,"isVote":1,"tweetType":1,"viewCount":163,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170222220,"gmtCreate":1626437828360,"gmtModify":1631890295599,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170222220","repostId":"170631779","repostType":1,"repost":{"id":170631779,"gmtCreate":1626425364991,"gmtModify":1631892324704,"author":{"id":"4087821855695230","authorId":"4087821855695230","authorIdStr":"4087821855695230","name":"Srikanth","avatar":"https://static.tigerbbs.com/4b3ea20f2e2f984cdc111f2c5e42e603","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087821855695230"},"themes":[],"htmlText":"This is moving crazy","listText":"This is moving crazy","text":"This is moving crazy","images":[{"img":"https://static.tigerbbs.com/685e8ab98579162550ec0b9203f5e640","width":"1125","height":"3291"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170631779","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170685583,"gmtCreate":1626426956542,"gmtModify":1631890295614,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Fk it","listText":"Fk it","text":"Fk it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170685583","repostId":"147650583","repostType":1,"repost":{"id":147650583,"gmtCreate":1626357043542,"gmtModify":1631886774526,"author":{"id":"3571894533961978","authorId":"3571894533961978","authorIdStr":"3571894533961978","name":"YongKhin","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571894533961978"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PTRA\">$Proterra Inc.(PTRA)$</a>9 more percent&nbsp;","listText":"<a href=\"https://laohu8.com/S/PTRA\">$Proterra Inc.(PTRA)$</a>9 more percent&nbsp;","text":"$Proterra Inc.(PTRA)$9 more percent","images":[{"img":"https://static.tigerbbs.com/2bc9c1120430efc9e93f10c18e44622e","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/147650583","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147613812,"gmtCreate":1626356009636,"gmtModify":1631890295630,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Nice nice","listText":"Nice nice","text":"Nice nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/147613812","repostId":"2151526974","repostType":4,"repost":{"id":"2151526974","pubTimestamp":1626355620,"share":"https://www.laohu8.com/m/news/2151526974?lang=&edition=full","pubTime":"2021-07-15 21:27","market":"us","language":"en","title":"3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2151526974","media":"Motley Fool","summary":"Analysts' high-water price targets imply some serious gains for these companies.","content":"<p>Despite the stock market hitting seemingly <a href=\"https://laohu8.com/S/AONE.U\">one</a> new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S. and global economy bode well for the growth stocks that have led the market higher.</p>\n<p>But growth isn't the only category analysts believe will outperform. Small-cap stocks -- companies with market caps ranging from $300 million to as high as $2 billion -- were absolutely pummeled during the coronavirus crash and now appear set to thrive. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await.</p>\n<h2>Vaxart: Implied upside of 158%</h2>\n<p>The first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock <b>Vaxart</b> (NASDAQ:VXRT). A little over a month ago, analyst Yasmeen Rahimi at Piper Sander placed an $18 price target and an overweight rating on Vaxart. Based on its $6.99 closing price on July 12, we're talking about roughly 158% in implied upside over the next year.</p>\n<p>For Rahimi, the selling point on Vaxart is the company's Vector-Adjuvant-Antigen Standardized Technology, or VAAST platform. This proprietary oral vaccine platform is deemed relatively low risk by Rahimi given the amount of clinical data readily available. Specifically, VAAST is designed to activate systemic and mucosal immunity in the nose, lungs, intestines, and mouth to help fight against airborne viruses, such as influenza and norovirus.</p>\n<p>But it's not norovirus that's put Vaxart on the map in 2021. That honor goes to VXA-CoV2-1, the company's clinical-stage coronavirus disease 2019 (COVID-19) candidate. Vaxart's experimental treatment is unique in that it's a pill, not an injection. A pill would likely result in higher vaccination rates, and it would certainly be easier from a distribution and administration standpoint.</p>\n<p>Back on May 3, Vaxart released data from its phase 1 study involving VXA-CoV2-1, which showed demonstrable CD8 T-cell responses. While it was able to generate relatively impressive immune responses, the company's pill didn't produce high levels of neutralizing antibodies in trial participants, which diverges from what we've seen following traditional COVID-19 injections.</p>\n<p>Though Vaxart may have a promising pathway to treat norovirus, it has a steep hill to climb if it's to become relevant in the COVID-19 treatment space. It's probably a bit early to pass judgment either way, but Rahimi's price target is potentially a bit too aggressive for a clinical-stage drug developer.</p>\n<h2>Columbia Care: Implied upside of 180%</h2>\n<p>Wall Street is also exceptionally bullish on the U.S. cannabis industry, with most multistate operators expected to fly. But one marijuana stock with particularly high upside, according to the high-water price target on Wall Street of more than $15 a share, is <b>Columbia Care</b> (OTC:CCHWF). If Wall Street's most aggressive price target comes to fruition, Columbia Care's shareholders could be reveling in a 180% gain over the coming 12 months.</p>\n<p>Columbia Care finds itself perfectly set up to take advantage of a rapidly growing cannabis market in the U.S. In total, 36 states have waved the green flag on medical weed, with half of those states legalizing consumption and/or adult-use sales. With Columbia Care primarily focused on serving medical pot customers for years, it was a pretty seamless transition to also servicing a larger pool of recreational weed clients.</p>\n<p>Although the company is generating healthy growth from its existing dispensaries -- 60% same-store sales growth in the first quarter from retail locations open in Q1 2020 -- its core strategy has involved making strategic acquisitions. Last month, the company closed a $240 million deal to acquire Green Leaf Medical, which added operational and in-development dispensaries in four states, as well as close to 400,000 square feet of cultivation and production capacity.</p>\n<p>Additionally, the purchase of The Green Solution in September 2020 stood out, as it allowed Columbia Care to gobble up Colorado's largest vertically integrated cannabis operator. Colorado sports the second-highest annual weed sales in the U.S., behind only California.</p>\n<p>The last thing to take note of is Columbia Care's focus on limited-license markets. States like Pennsylvania and Ohio cap the number of retail licenses they'll issue, as well as how many licenses a single business can hold. Meanwhile, Virginia assigns licenses by jurisdiction. The point is this: Columbia Care will be able to establish a presence in key markets without being overrun by competition.</p>\n<p>To be clear, I believe Columbia Care has a very bright future. However, expecting a 180% climb in 12 months might be a bit much.</p>\n<h2>Inovio Pharmaceuticals: Implied upside of 329%</h2>\n<p>But the crème de la crème of upside opportunity, at least on this list, belongs to clinical-stage biotech stock <b>Inovio Pharmaceuticals</b> (NASDAQ:INO). According to Oppenheimer analyst Hartaj Singh, Inovio has a price target of $35, implying that it'll more than quadruple in value over the next year.</p>\n<p>The bulk of Singh's thesis rests with INO-4800, the company's experimental COVID-19 vaccine candidate. Since Inovio's vaccines are DNA-based, Singh believes they can be modified easily to tackle new variants of the disease as they arise. Further, Singh points out that INO-4800 has a more stable shelf life than some of the more popular COVID-19 vaccines. For context, Inovio reported on May 10 that its mid-stage study involving INO-4800 was well-tolerated, with T cell immune responses observed in all age groups.</p>\n<p>Inovio also has a relatively large pipeline for a company with a sub-$2 billion market cap. It has nearly a dozen different DNA-based candidates in clinical trials at the moment to treat everything from infectious diseases to cancer. Generally speaking, the more swings a drug developer gets to take, the more likely they are to hit a home run.</p>\n<p>On the other hand, Inovio Pharmaceuticals has struck out swinging for more than four decades. This is to say that Inovio has yet to bring an approved product to market since its inception more than 40 years ago.</p>\n<p>What's more, INO-4800 wasn't exactly getting the red carpet treatment in the lucrative U.S. market. The U.S. Food and Drug Administration placed a partial clinical hold on Inovio's phase 2/3 trial to gather more info on INO-4800 and its delivery device, known as Cellectra. Months later, the U.S. government pulled funding for a late-stage trial of INO-4800, coercing the company to look internationally to conduct its large-scale study.</p>\n<p>In other words, with a long history of disappointment in its wake, Inovio is the type of stock investors should avoid until it actually shows us the goods.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-15 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药","VXRT":"Vaxart, Inc"},"source_url":"https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151526974","content_text":"Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S. and global economy bode well for the growth stocks that have led the market higher.\nBut growth isn't the only category analysts believe will outperform. Small-cap stocks -- companies with market caps ranging from $300 million to as high as $2 billion -- were absolutely pummeled during the coronavirus crash and now appear set to thrive. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await.\nVaxart: Implied upside of 158%\nThe first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock Vaxart (NASDAQ:VXRT). A little over a month ago, analyst Yasmeen Rahimi at Piper Sander placed an $18 price target and an overweight rating on Vaxart. Based on its $6.99 closing price on July 12, we're talking about roughly 158% in implied upside over the next year.\nFor Rahimi, the selling point on Vaxart is the company's Vector-Adjuvant-Antigen Standardized Technology, or VAAST platform. This proprietary oral vaccine platform is deemed relatively low risk by Rahimi given the amount of clinical data readily available. Specifically, VAAST is designed to activate systemic and mucosal immunity in the nose, lungs, intestines, and mouth to help fight against airborne viruses, such as influenza and norovirus.\nBut it's not norovirus that's put Vaxart on the map in 2021. That honor goes to VXA-CoV2-1, the company's clinical-stage coronavirus disease 2019 (COVID-19) candidate. Vaxart's experimental treatment is unique in that it's a pill, not an injection. A pill would likely result in higher vaccination rates, and it would certainly be easier from a distribution and administration standpoint.\nBack on May 3, Vaxart released data from its phase 1 study involving VXA-CoV2-1, which showed demonstrable CD8 T-cell responses. While it was able to generate relatively impressive immune responses, the company's pill didn't produce high levels of neutralizing antibodies in trial participants, which diverges from what we've seen following traditional COVID-19 injections.\nThough Vaxart may have a promising pathway to treat norovirus, it has a steep hill to climb if it's to become relevant in the COVID-19 treatment space. It's probably a bit early to pass judgment either way, but Rahimi's price target is potentially a bit too aggressive for a clinical-stage drug developer.\nColumbia Care: Implied upside of 180%\nWall Street is also exceptionally bullish on the U.S. cannabis industry, with most multistate operators expected to fly. But one marijuana stock with particularly high upside, according to the high-water price target on Wall Street of more than $15 a share, is Columbia Care (OTC:CCHWF). If Wall Street's most aggressive price target comes to fruition, Columbia Care's shareholders could be reveling in a 180% gain over the coming 12 months.\nColumbia Care finds itself perfectly set up to take advantage of a rapidly growing cannabis market in the U.S. In total, 36 states have waved the green flag on medical weed, with half of those states legalizing consumption and/or adult-use sales. With Columbia Care primarily focused on serving medical pot customers for years, it was a pretty seamless transition to also servicing a larger pool of recreational weed clients.\nAlthough the company is generating healthy growth from its existing dispensaries -- 60% same-store sales growth in the first quarter from retail locations open in Q1 2020 -- its core strategy has involved making strategic acquisitions. Last month, the company closed a $240 million deal to acquire Green Leaf Medical, which added operational and in-development dispensaries in four states, as well as close to 400,000 square feet of cultivation and production capacity.\nAdditionally, the purchase of The Green Solution in September 2020 stood out, as it allowed Columbia Care to gobble up Colorado's largest vertically integrated cannabis operator. Colorado sports the second-highest annual weed sales in the U.S., behind only California.\nThe last thing to take note of is Columbia Care's focus on limited-license markets. States like Pennsylvania and Ohio cap the number of retail licenses they'll issue, as well as how many licenses a single business can hold. Meanwhile, Virginia assigns licenses by jurisdiction. The point is this: Columbia Care will be able to establish a presence in key markets without being overrun by competition.\nTo be clear, I believe Columbia Care has a very bright future. However, expecting a 180% climb in 12 months might be a bit much.\nInovio Pharmaceuticals: Implied upside of 329%\nBut the crème de la crème of upside opportunity, at least on this list, belongs to clinical-stage biotech stock Inovio Pharmaceuticals (NASDAQ:INO). According to Oppenheimer analyst Hartaj Singh, Inovio has a price target of $35, implying that it'll more than quadruple in value over the next year.\nThe bulk of Singh's thesis rests with INO-4800, the company's experimental COVID-19 vaccine candidate. Since Inovio's vaccines are DNA-based, Singh believes they can be modified easily to tackle new variants of the disease as they arise. Further, Singh points out that INO-4800 has a more stable shelf life than some of the more popular COVID-19 vaccines. For context, Inovio reported on May 10 that its mid-stage study involving INO-4800 was well-tolerated, with T cell immune responses observed in all age groups.\nInovio also has a relatively large pipeline for a company with a sub-$2 billion market cap. It has nearly a dozen different DNA-based candidates in clinical trials at the moment to treat everything from infectious diseases to cancer. Generally speaking, the more swings a drug developer gets to take, the more likely they are to hit a home run.\nOn the other hand, Inovio Pharmaceuticals has struck out swinging for more than four decades. This is to say that Inovio has yet to bring an approved product to market since its inception more than 40 years ago.\nWhat's more, INO-4800 wasn't exactly getting the red carpet treatment in the lucrative U.S. market. The U.S. Food and Drug Administration placed a partial clinical hold on Inovio's phase 2/3 trial to gather more info on INO-4800 and its delivery device, known as Cellectra. Months later, the U.S. government pulled funding for a late-stage trial of INO-4800, coercing the company to look internationally to conduct its large-scale study.\nIn other words, with a long history of disappointment in its wake, Inovio is the type of stock investors should avoid until it actually shows us the goods.","news_type":1},"isVote":1,"tweetType":1,"viewCount":51,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143211379,"gmtCreate":1625795647391,"gmtModify":1631890295638,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Nice Man","listText":"Nice Man","text":"Nice Man","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143211379","repostId":"1153646457","repostType":4,"isVote":1,"tweetType":1,"viewCount":9,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140244522,"gmtCreate":1625664427066,"gmtModify":1631890295646,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Comment like and comment like and comment","listText":"Comment like and comment like and comment","text":"Comment like and comment like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/140244522","repostId":"1156748810","repostType":4,"isVote":1,"tweetType":1,"viewCount":75,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140242664,"gmtCreate":1625664286458,"gmtModify":1631890295660,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Nice nice nice, posting for tiger coins","listText":"Nice nice nice, posting for tiger coins","text":"Nice nice nice, posting for tiger coins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/140242664","repostId":"2149390140","repostType":4,"isVote":1,"tweetType":1,"viewCount":18,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140246581,"gmtCreate":1625664236543,"gmtModify":1631890295671,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Nice nice nice nice nice. Tiger coins nice.","listText":"Nice nice nice nice nice. Tiger coins nice.","text":"Nice nice nice nice nice. Tiger coins nice.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/140246581","repostId":"2149160390","repostType":4,"isVote":1,"tweetType":1,"viewCount":264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158619431,"gmtCreate":1625147438623,"gmtModify":1631890295682,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158619431","repostId":"1175411154","repostType":4,"repost":{"id":"1175411154","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625146583,"share":"https://www.laohu8.com/m/news/1175411154?lang=&edition=full","pubTime":"2021-07-01 21:36","market":"us","language":"en","title":"EV Stocks surged in Thursday morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1175411154","media":"Tiger Newspress","summary":"EV Stocks surged in Thursday morning trading on Due to vehicle delivery.Tesla,Nio,Xpeng Motors and L","content":"<p>EV Stocks surged in Thursday morning trading&nbsp;on Due to vehicle delivery.Tesla,Nio,Xpeng Motors and Li Auto&nbsp;climbed between 1% and 6%.</p>\n<p><img src=\"https://static.tigerbbs.com/a850dc2f94b465cace256883ee0685a8\" tg-width=\"371\" tg-height=\"309\" referrerpolicy=\"no-referrer\"></p>\n<p>NIO delivered 8,083 vehicles in June 2021, increasing by 116.1% year-over-year;</p>\n<p>Xpeng&nbsp;delivered&nbsp;6,565 vehicles in June 2021, a record month with a 617% increase year-over-year;</p>\n<p>Wall Street expects&nbsp;Tesla Inc. to report deliveries of roughly 200,000 vehicles in the latest quarter, which would be a milestone for the electric-car makerled by Chief Executive Officer Elon Musk.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV Stocks surged in Thursday morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV Stocks surged in Thursday morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-01 21:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV Stocks surged in Thursday morning trading&nbsp;on Due to vehicle delivery.Tesla,Nio,Xpeng Motors and Li Auto&nbsp;climbed between 1% and 6%.</p>\n<p><img src=\"https://static.tigerbbs.com/a850dc2f94b465cace256883ee0685a8\" tg-width=\"371\" tg-height=\"309\" referrerpolicy=\"no-referrer\"></p>\n<p>NIO delivered 8,083 vehicles in June 2021, increasing by 116.1% year-over-year;</p>\n<p>Xpeng&nbsp;delivered&nbsp;6,565 vehicles in June 2021, a record month with a 617% increase year-over-year;</p>\n<p>Wall Street expects&nbsp;Tesla Inc. to report deliveries of roughly 200,000 vehicles in the latest quarter, which would be a milestone for the electric-car makerled by Chief Executive Officer Elon Musk.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LI":"理想汽车","NIO":"蔚来","TSLA":"特斯拉","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175411154","content_text":"EV Stocks surged in Thursday morning trading on Due to vehicle delivery.Tesla,Nio,Xpeng Motors and Li Auto climbed between 1% and 6%.\n\nNIO delivered 8,083 vehicles in June 2021, increasing by 116.1% year-over-year;\nXpeng delivered 6,565 vehicles in June 2021, a record month with a 617% increase year-over-year;\nWall Street expects Tesla Inc. to report deliveries of roughly 200,000 vehicles in the latest quarter, which would be a milestone for the electric-car makerled by Chief Executive Officer Elon Musk.","news_type":1},"isVote":1,"tweetType":1,"viewCount":27,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158610714,"gmtCreate":1625147415938,"gmtModify":1631890295695,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Oh dear","listText":"Oh dear","text":"Oh dear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158610714","repostId":"1106960651","repostType":4,"repost":{"id":"1106960651","pubTimestamp":1625147164,"share":"https://www.laohu8.com/m/news/1106960651?lang=&edition=full","pubTime":"2021-07-01 21:46","market":"us","language":"en","title":"Barclays says ZipRecruiter’s stock price can jump 20% amid U.S. labor supply and demand mismatch","url":"https://stock-news.laohu8.com/highlight/detail?id=1106960651","media":"CNBC","summary":"Barclays initiated coverage of ZipRecruiter on Thursday, saying the online recruiting platform is we","content":"<div>\n<p>Barclays initiated coverage of ZipRecruiter on Thursday, saying the online recruiting platform is well-positioned to gain as U.S. employers face challenges filling job openings.\n“ZIP is differentiated...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/01/barclays-says-ziprecruiter-stock-price-can-jump-20percent.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Barclays says ZipRecruiter’s stock price can jump 20% amid U.S. labor supply and demand mismatch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBarclays says ZipRecruiter’s stock price can jump 20% amid U.S. labor supply and demand mismatch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-01 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/01/barclays-says-ziprecruiter-stock-price-can-jump-20percent.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Barclays initiated coverage of ZipRecruiter on Thursday, saying the online recruiting platform is well-positioned to gain as U.S. employers face challenges filling job openings.\n“ZIP is differentiated...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/01/barclays-says-ziprecruiter-stock-price-can-jump-20percent.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZIP":"ZipRecruiter Inc."},"source_url":"https://www.cnbc.com/2021/07/01/barclays-says-ziprecruiter-stock-price-can-jump-20percent.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1106960651","content_text":"Barclays initiated coverage of ZipRecruiter on Thursday, saying the online recruiting platform is well-positioned to gain as U.S. employers face challenges filling job openings.\n“ZIP is differentiated from online peers (as well as traditional internal⁄third-party recruiting services) by its AI-based matching, resulting in faster⁄better quality candidate recommendations and faster time-to-hire, alleviating key pain points for employer-customers,” Barclays’ Trevor Young said in a note released Thursday.\nThe firm gave ZipRecruiter an overweight rating and set its 12-month price target at $30, implying upside of 20%.\nBarclays’ call comes as the labor market remains in focus, with U.S. employers citing worker shortages and difficulty replacing lost jobs from the pandemic.\nAs job openings outpace job seeker demand, Barclays says the current employment trend “sets up favorable dynamics” for ZipRecruiter.\n“We believe more and more employers will explore additional resources, such as ZipRecruiter, to try to source candidates that are willing and able to work,” Young said.\nBarclays lauded ZipRecruiter’s strong technological capabilities and brand awareness among employers as differentiators from peer job marketplaces.\nWith work-from-home continuing, the firm said greater geographic mobility should keep demand for online recruiting tools high in the near future.\nZipRecruiter debuted on the New York Stock Exchange in May. The stock price closed at $24.98 on Wednesday and gained 8.4% in June.","news_type":1},"isVote":1,"tweetType":1,"viewCount":26,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126951939,"gmtCreate":1624542881321,"gmtModify":1631894034426,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>zzzz pls up","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>zzzz pls up","text":"$Tiger Brokers(TIGR)$zzzz pls up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126951939","isVote":1,"tweetType":1,"viewCount":9,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128748969,"gmtCreate":1624534136951,"gmtModify":1631885865502,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>uupupup","listText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>uupupup","text":"$Intel(INTC)$uupupup","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128748969","isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128741450,"gmtCreate":1624534114270,"gmtModify":1631884082287,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"New comment","listText":"New comment","text":"New comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128741450","isVote":1,"tweetType":1,"viewCount":159,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128743796,"gmtCreate":1624534065915,"gmtModify":1631894034439,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128743796","repostId":"1187819280","repostType":4,"repost":{"id":"1187819280","pubTimestamp":1624529642,"share":"https://www.laohu8.com/m/news/1187819280?lang=&edition=full","pubTime":"2021-06-24 18:14","market":"us","language":"en","title":"The ‘shelter in suburbia’ trade is about to reverse — and these stocks will suffer","url":"https://stock-news.laohu8.com/highlight/detail?id=1187819280","media":"MarketWatch","summary":"5 reasons the pandemic megatrend is over.\n\nOne of the biggest investment stories of the COVID-19 pan","content":"<blockquote>\n <b>5 reasons the pandemic megatrend is over.</b>\n</blockquote>\n<p>One of the biggest investment stories of the COVID-19 pandemic has been the boom in consumer discretionary stocks with a “shelter in suburbia” theme. From e-commerce platforms to home improvement stores to furniture and housewares merchants, many of the top performers have fit this flavor.</p>\n<p>Take the broad-based Vanguard Consumer Discretionary Index Fund ETF VCR, +0.66% that surged more than 90% from March 2020 to March 2021. That was thanks to components like home improvement stocks Lowe’s LOW, -0.30% and Home Depot HD, -0.33% alongside retailers like TJX TJX, -0.08%.</p>\n<p>Lately, however, performance has started to lag for many of these names. In fact, since April 1 we’ve seen these three stocks all drift slightly into the red even as the S&amp;P 500 SPX, -0.11% has tacked on about 6% in the same period.</p>\n<p>And some fear that may only be the beginning. As one Wall Street insider said recently in a Bloomberg interview, a “huge unwind” is coming for stay-at-home stocks, including hardware stores and home-goods merchants.</p>\n<p>While some big-name “suburbia” trades are still relatively stable, signs of trouble are already emerging at the fringes. Century Communities CCS, -0.34% and Dream Finders Homes DFH, -2.55%, two mid-tier single family homebuilders, have seen shares crash by double digits over the last month. On the furnishings side, appliance giant Whirlpool Corporation WHR, -0.51% and department store Nordstrom JWN, +2.03% are down sharply from their spring highs.</p>\n<p><b>Here are five big reasons why:</b></p>\n<p><b>1.</b>&nbsp;<b>The upgrade cycle is over</b></p>\n<p>Last summer, white-collar workers who were stuck at home made note of overdue projects and took advantage of being able to easily meet with contractors. But in many ways, this growth is not sustainable.</p>\n<p>Consider the kind of purchases homeowners were making according to data from the NPD Group. Faucets, kitchen cabinets and even toilets were among the most popular products sold in 2020. Needless to say, even the most profligate homeowners aren’t going to follow this upgrade cycle of remodeling kitchens and bathrooms on an annual basis.</p>\n<p>The same is true for furniture and other home goods. Internet giant Comscore recorded the highest visitation to related websites in history in May 2020 with 133 million web surfers shopping for some kind of home goods. Once again, a new couch or lamp is not an annual purchase — so this trend seems unsustainable for much longer.</p>\n<p><b>2.&nbsp;Valuations are stretched</b></p>\n<p>Speaking of post-pandemic peaks for home-goods purveyors, we’ve seen the financials bear out these big increases via boosted profits and sales. However, we’ve also seen the stock of many related merchants surge even more — stretching their valuations from historical norms.</p>\n<p>Take TJX. Currently this discount retailer has a forward price-to-earnings ratio of more than 26, compared with a forward P/E of just 21 in spring 2020. Its trailing price-to-sales ratio is now 2.1 compared with 1.4.</p>\n<p>What’s more, valuations for previous darlings like TJX are out of line with peers, too. Consider the forward P/E of the overall S&amp;P 500 index is 22 right now, and other similar names like Macy’s M, +0.70% and Big Lots BIG, -3.71% actually have forward P/E ratios well under 10. You can argue TJX is unique, of course… but you also may want to be aware of what “fair value” looks like for many other stocks outside fashionable stay-at-home trades right now.</p>\n<p><b>3.&nbsp;Delays and shortages</b></p>\n<p>Future growth from pandemic-fueled peaks in these stocks is not impossible, of course. But given supply chain disruptions it seems highly unlikely. There are a host of reasons for these delays, including overseas shipping delays as well as capacity and output crunches that are affecting many industries, but “stay at home” stocks seem particularly hard hit.</p>\n<p>Home improvement products are simply nowhere to be found, with roughly 94% of builders reporting “at least some serious shortages of appliances” according to the National Association of Home Builders. Another 93% are running short on framing lumber and 87% say it is hard to obtain windows and doors.</p>\n<p>Even if you can get past demand concerns, without the raw materials to get to work it’s very hard to see future growth in this category.</p>\n<p><b>4.&nbsp;Inflationary pressures</b></p>\n<p>For the people who haven’t already ponied up the cash for a contractor or made their peace with extended delays for their expensive new furniture, there is a pretty big disincentive right now for new shoppers: inflation.</p>\n<p>The cost of living as measured by the Consumer Price Index jumped 0.6% in May to run at a 5% annual rate. That was not only higher than expectations, but the fastest pace since the summer of 2008. The inflation risks were so pronounced that the Federal Reserve publicly stated it could move up the schedule for expected interest rate increases to keep the risks under wraps.</p>\n<p>Inflation isn’t always a death knell, of course. But it has historically eroded purchasing power and could curtail some of the spending in “stay at home” stocks that we’ve seen in the last year or so.</p>\n<p><b>5.&nbsp;Home-equity hubris</b></p>\n<p>Speaking of red-hot inflation: In May, the median price for U.S. homes topped $350,000 for the first time ever — up 23.6% from 2020. What’s more, a Realtor.com survey showed roughly a third of selling homeowners expect to get more than their asking price, and roughly the same amount expect an offer within a week of listing.</p>\n<p>Some of this is justifiable. Many articles have been written in recent years about the dearth of supply in attractive markets, and it’s important to acknowledge the remote work of the pandemic has indeed created some disruptive introspection into why people live where they do.</p>\n<p>But here’s where things get dicey: homeowners who have already spent the expected premium on their home’s price well in advance. According to Freddie Mac, about $152.7 billion in equity loans were taken out on U.S. houses last year, a massive increase of 41.7% from 2019 and the highest refinancing cash-out dollar amount since 2007.</p>\n<p>Anyone remember what happened to the real-estate market in 2007? Or the similar sense of seller entitlement from those days? There’s no clear signs of a bubble bursting just yet, but there’s real risk American homeowners may be overly optimistic about what their homes are worth — and a chance this home equity loan free-for-all simply isn’t sustainable for much longer.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The ‘shelter in suburbia’ trade is about to reverse — and these stocks will suffer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe ‘shelter in suburbia’ trade is about to reverse — and these stocks will suffer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 18:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/the-shelter-in-suburbia-trade-is-about-to-reverse-and-these-stocks-will-suffer-11624457411?siteid=yhoof2><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5 reasons the pandemic megatrend is over.\n\nOne of the biggest investment stories of the COVID-19 pandemic has been the boom in consumer discretionary stocks with a “shelter in suburbia” theme. From e-...</p>\n\n<a href=\"https://www.marketwatch.com/story/the-shelter-in-suburbia-trade-is-about-to-reverse-and-these-stocks-will-suffer-11624457411?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/the-shelter-in-suburbia-trade-is-about-to-reverse-and-these-stocks-will-suffer-11624457411?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187819280","content_text":"5 reasons the pandemic megatrend is over.\n\nOne of the biggest investment stories of the COVID-19 pandemic has been the boom in consumer discretionary stocks with a “shelter in suburbia” theme. From e-commerce platforms to home improvement stores to furniture and housewares merchants, many of the top performers have fit this flavor.\nTake the broad-based Vanguard Consumer Discretionary Index Fund ETF VCR, +0.66% that surged more than 90% from March 2020 to March 2021. That was thanks to components like home improvement stocks Lowe’s LOW, -0.30% and Home Depot HD, -0.33% alongside retailers like TJX TJX, -0.08%.\nLately, however, performance has started to lag for many of these names. In fact, since April 1 we’ve seen these three stocks all drift slightly into the red even as the S&P 500 SPX, -0.11% has tacked on about 6% in the same period.\nAnd some fear that may only be the beginning. As one Wall Street insider said recently in a Bloomberg interview, a “huge unwind” is coming for stay-at-home stocks, including hardware stores and home-goods merchants.\nWhile some big-name “suburbia” trades are still relatively stable, signs of trouble are already emerging at the fringes. Century Communities CCS, -0.34% and Dream Finders Homes DFH, -2.55%, two mid-tier single family homebuilders, have seen shares crash by double digits over the last month. On the furnishings side, appliance giant Whirlpool Corporation WHR, -0.51% and department store Nordstrom JWN, +2.03% are down sharply from their spring highs.\nHere are five big reasons why:\n1. The upgrade cycle is over\nLast summer, white-collar workers who were stuck at home made note of overdue projects and took advantage of being able to easily meet with contractors. But in many ways, this growth is not sustainable.\nConsider the kind of purchases homeowners were making according to data from the NPD Group. Faucets, kitchen cabinets and even toilets were among the most popular products sold in 2020. Needless to say, even the most profligate homeowners aren’t going to follow this upgrade cycle of remodeling kitchens and bathrooms on an annual basis.\nThe same is true for furniture and other home goods. Internet giant Comscore recorded the highest visitation to related websites in history in May 2020 with 133 million web surfers shopping for some kind of home goods. Once again, a new couch or lamp is not an annual purchase — so this trend seems unsustainable for much longer.\n2. Valuations are stretched\nSpeaking of post-pandemic peaks for home-goods purveyors, we’ve seen the financials bear out these big increases via boosted profits and sales. However, we’ve also seen the stock of many related merchants surge even more — stretching their valuations from historical norms.\nTake TJX. Currently this discount retailer has a forward price-to-earnings ratio of more than 26, compared with a forward P/E of just 21 in spring 2020. Its trailing price-to-sales ratio is now 2.1 compared with 1.4.\nWhat’s more, valuations for previous darlings like TJX are out of line with peers, too. Consider the forward P/E of the overall S&P 500 index is 22 right now, and other similar names like Macy’s M, +0.70% and Big Lots BIG, -3.71% actually have forward P/E ratios well under 10. You can argue TJX is unique, of course… but you also may want to be aware of what “fair value” looks like for many other stocks outside fashionable stay-at-home trades right now.\n3. Delays and shortages\nFuture growth from pandemic-fueled peaks in these stocks is not impossible, of course. But given supply chain disruptions it seems highly unlikely. There are a host of reasons for these delays, including overseas shipping delays as well as capacity and output crunches that are affecting many industries, but “stay at home” stocks seem particularly hard hit.\nHome improvement products are simply nowhere to be found, with roughly 94% of builders reporting “at least some serious shortages of appliances” according to the National Association of Home Builders. Another 93% are running short on framing lumber and 87% say it is hard to obtain windows and doors.\nEven if you can get past demand concerns, without the raw materials to get to work it’s very hard to see future growth in this category.\n4. Inflationary pressures\nFor the people who haven’t already ponied up the cash for a contractor or made their peace with extended delays for their expensive new furniture, there is a pretty big disincentive right now for new shoppers: inflation.\nThe cost of living as measured by the Consumer Price Index jumped 0.6% in May to run at a 5% annual rate. That was not only higher than expectations, but the fastest pace since the summer of 2008. The inflation risks were so pronounced that the Federal Reserve publicly stated it could move up the schedule for expected interest rate increases to keep the risks under wraps.\nInflation isn’t always a death knell, of course. But it has historically eroded purchasing power and could curtail some of the spending in “stay at home” stocks that we’ve seen in the last year or so.\n5. Home-equity hubris\nSpeaking of red-hot inflation: In May, the median price for U.S. homes topped $350,000 for the first time ever — up 23.6% from 2020. What’s more, a Realtor.com survey showed roughly a third of selling homeowners expect to get more than their asking price, and roughly the same amount expect an offer within a week of listing.\nSome of this is justifiable. Many articles have been written in recent years about the dearth of supply in attractive markets, and it’s important to acknowledge the remote work of the pandemic has indeed created some disruptive introspection into why people live where they do.\nBut here’s where things get dicey: homeowners who have already spent the expected premium on their home’s price well in advance. According to Freddie Mac, about $152.7 billion in equity loans were taken out on U.S. houses last year, a massive increase of 41.7% from 2019 and the highest refinancing cash-out dollar amount since 2007.\nAnyone remember what happened to the real-estate market in 2007? Or the similar sense of seller entitlement from those days? There’s no clear signs of a bubble bursting just yet, but there’s real risk American homeowners may be overly optimistic about what their homes are worth — and a chance this home equity loan free-for-all simply isn’t sustainable for much longer.","news_type":1},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":188073338,"gmtCreate":1623418319924,"gmtModify":1631886774698,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ACTC\">$ArcLight Clean Transition Corp(ACTC)$</a>today vote for merger, fly","listText":"<a href=\"https://laohu8.com/S/ACTC\">$ArcLight Clean Transition Corp(ACTC)$</a>today vote for merger, fly","text":"$ArcLight Clean Transition Corp(ACTC)$today vote for merger, fly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/188073338","isVote":1,"tweetType":1,"viewCount":488,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":854029178,"gmtCreate":1635411502561,"gmtModify":1635411685942,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>eehh.. i tot Tiger got HongKong License? In other words like not really impacted? Lol","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>eehh.. i tot Tiger got HongKong License? In other words like not really impacted? Lol","text":"$Tiger Brokers(TIGR)$eehh.. i tot Tiger got HongKong License? In other words like not really impacted? Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854029178","isVote":1,"tweetType":1,"viewCount":2255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824877060,"gmtCreate":1634305910155,"gmtModify":1634306364271,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>around 50-60% shorts for float. Gamma squeeze target.","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>around 50-60% shorts for float. Gamma squeeze target.","text":"$Tiger Brokers(TIGR)$around 50-60% shorts for float. Gamma squeeze target.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/824877060","isVote":1,"tweetType":1,"viewCount":857,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":128743032,"gmtCreate":1624534004826,"gmtModify":1631894034453,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/128743032","repostId":"1184881454","repostType":4,"repost":{"id":"1184881454","pubTimestamp":1624533663,"share":"https://www.laohu8.com/m/news/1184881454?lang=&edition=full","pubTime":"2021-06-24 19:21","market":"us","language":"en","title":"Comcast Says 'Pure Speculation' It's Mulling Bids for ViacomCBS or Roku","url":"https://stock-news.laohu8.com/highlight/detail?id=1184881454","media":"The Street","summary":"ViacomCBS and Roku are both in the spotlight on a report that Comcast is pondering a bid for one of ","content":"<blockquote>\n <b>ViacomCBS and Roku are both in the spotlight on a report that Comcast is pondering a bid for one of the companies, even as Comcast calls it \"pure speculation.\"</b>\n</blockquote>\n<p>ViacomCBS&nbsp;(<b>VIACA</b>) -Get Report&nbsp;and Roku&nbsp;(<b>ROKU</b>) -Get Report&nbsp;were both in the spotlight on Thursday following a report that Comcast&nbsp;(<b>CMCSA</b>) -Get Report&nbsp;was pondering a bid for one of the companies.</p>\n<p>Comcast called the possibility \"pure speculation.\"</p>\n<p>Citing unnamed sources, The Wall Street Journal on Wednesday reported that Comcast CEO Brian Roberts has considered a transaction with ViacomCBS or an acquisition of Roku, though at the same time has made clear that Comcast doesn’t need to pursue a merger to grow its TV, movie and streaming portfolio.</p>\n<p>A Comcast spokesperson told CNBC on Wednesday that the discussions were \"pure speculation.\"&nbsp;Even so, the possibility of another big media merger pushed both ViacomCBS and Roku shares higher.</p>\n<p>ViacomCBS shares ended the trading day Wednesday up 2.7% to $41.84, their biggest one-day gain in almost a month.&nbsp;Roku shares ended the trading day Wednesday up 4.5% at $421.70. The stock was up 1.02% at $425.99 in premarket trading on Thursday.</p>\n<p>The speculation follows a flurry of recent merger activity in the media space, including Amazon’s&nbsp;(<b>AMZN</b>) -Get Report&nbsp;pending $8.45 billion acquisition of Metro-Goldwyn-Mayer&nbsp;and AT&amp;T’s&nbsp;(<b>T</b>) -Get Report&nbsp;agreement to combine its WarnerMedia division with Discovery&nbsp;(<b>DISCA</b>) -Get Report. ViacomCBS itself was created out of a merger of Viacom and CBS completed in late 2019.</p>\n<p>Comcast owns NBCUniversal, a sprawling entertainment operation that includes TV and movies, though its Peacock streaming service is playing catch-up with Netflix&nbsp;(<b>NFLX</b>) -Get Report&nbsp;and Walt Disney&nbsp;(<b>DIS</b>) -Get Report, in particular Disney's Disney+ service.</p>\n<p>At the same time, Roberts is contemplating whether to continue to build out its offerings internally, particularly on the streaming side, or whether to buy something like ViacomCBS,whose stock has plunged since topping out at $101.97 on March 15.</p>\n<p>ViacomCBS and Discovery both posted double-digit percentage losses in March after margin calls against family office Archegos Capital Managementsparked forced block sales of both companies' shares.</p>\n<p>Shares of Comcast were up 1.66% at $56.40 in premarket trading. The stock ended the trading day Wednesday down 3.73% at $55.48.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Comcast Says 'Pure Speculation' It's Mulling Bids for ViacomCBS or Roku</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nComcast Says 'Pure Speculation' It's Mulling Bids for ViacomCBS or Roku\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/viacomcbs-roku-comcast-takeover-reports-062421><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ViacomCBS and Roku are both in the spotlight on a report that Comcast is pondering a bid for one of the companies, even as Comcast calls it \"pure speculation.\"\n\nViacomCBS (VIACA) -Get Report and Roku ...</p>\n\n<a href=\"https://www.thestreet.com/investing/viacomcbs-roku-comcast-takeover-reports-062421\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CMCSA":"康卡斯特","ROKU":"Roku Inc"},"source_url":"https://www.thestreet.com/investing/viacomcbs-roku-comcast-takeover-reports-062421","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184881454","content_text":"ViacomCBS and Roku are both in the spotlight on a report that Comcast is pondering a bid for one of the companies, even as Comcast calls it \"pure speculation.\"\n\nViacomCBS (VIACA) -Get Report and Roku (ROKU) -Get Report were both in the spotlight on Thursday following a report that Comcast (CMCSA) -Get Report was pondering a bid for one of the companies.\nComcast called the possibility \"pure speculation.\"\nCiting unnamed sources, The Wall Street Journal on Wednesday reported that Comcast CEO Brian Roberts has considered a transaction with ViacomCBS or an acquisition of Roku, though at the same time has made clear that Comcast doesn’t need to pursue a merger to grow its TV, movie and streaming portfolio.\nA Comcast spokesperson told CNBC on Wednesday that the discussions were \"pure speculation.\" Even so, the possibility of another big media merger pushed both ViacomCBS and Roku shares higher.\nViacomCBS shares ended the trading day Wednesday up 2.7% to $41.84, their biggest one-day gain in almost a month. Roku shares ended the trading day Wednesday up 4.5% at $421.70. The stock was up 1.02% at $425.99 in premarket trading on Thursday.\nThe speculation follows a flurry of recent merger activity in the media space, including Amazon’s (AMZN) -Get Report pending $8.45 billion acquisition of Metro-Goldwyn-Mayer and AT&T’s (T) -Get Report agreement to combine its WarnerMedia division with Discovery (DISCA) -Get Report. ViacomCBS itself was created out of a merger of Viacom and CBS completed in late 2019.\nComcast owns NBCUniversal, a sprawling entertainment operation that includes TV and movies, though its Peacock streaming service is playing catch-up with Netflix (NFLX) -Get Report and Walt Disney (DIS) -Get Report, in particular Disney's Disney+ service.\nAt the same time, Roberts is contemplating whether to continue to build out its offerings internally, particularly on the streaming side, or whether to buy something like ViacomCBS,whose stock has plunged since topping out at $101.97 on March 15.\nViacomCBS and Discovery both posted double-digit percentage losses in March after margin calls against family office Archegos Capital Managementsparked forced block sales of both companies' shares.\nShares of Comcast were up 1.66% at $56.40 in premarket trading. The stock ended the trading day Wednesday down 3.73% at $55.48.","news_type":1},"isVote":1,"tweetType":1,"viewCount":105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147613812,"gmtCreate":1626356009636,"gmtModify":1631890295630,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Nice nice","listText":"Nice nice","text":"Nice nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/147613812","repostId":"2151526974","repostType":4,"repost":{"id":"2151526974","pubTimestamp":1626355620,"share":"https://www.laohu8.com/m/news/2151526974?lang=&edition=full","pubTime":"2021-07-15 21:27","market":"us","language":"en","title":"3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2151526974","media":"Motley Fool","summary":"Analysts' high-water price targets imply some serious gains for these companies.","content":"<p>Despite the stock market hitting seemingly <a href=\"https://laohu8.com/S/AONE.U\">one</a> new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S. and global economy bode well for the growth stocks that have led the market higher.</p>\n<p>But growth isn't the only category analysts believe will outperform. Small-cap stocks -- companies with market caps ranging from $300 million to as high as $2 billion -- were absolutely pummeled during the coronavirus crash and now appear set to thrive. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await.</p>\n<h2>Vaxart: Implied upside of 158%</h2>\n<p>The first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock <b>Vaxart</b> (NASDAQ:VXRT). A little over a month ago, analyst Yasmeen Rahimi at Piper Sander placed an $18 price target and an overweight rating on Vaxart. Based on its $6.99 closing price on July 12, we're talking about roughly 158% in implied upside over the next year.</p>\n<p>For Rahimi, the selling point on Vaxart is the company's Vector-Adjuvant-Antigen Standardized Technology, or VAAST platform. This proprietary oral vaccine platform is deemed relatively low risk by Rahimi given the amount of clinical data readily available. Specifically, VAAST is designed to activate systemic and mucosal immunity in the nose, lungs, intestines, and mouth to help fight against airborne viruses, such as influenza and norovirus.</p>\n<p>But it's not norovirus that's put Vaxart on the map in 2021. That honor goes to VXA-CoV2-1, the company's clinical-stage coronavirus disease 2019 (COVID-19) candidate. Vaxart's experimental treatment is unique in that it's a pill, not an injection. A pill would likely result in higher vaccination rates, and it would certainly be easier from a distribution and administration standpoint.</p>\n<p>Back on May 3, Vaxart released data from its phase 1 study involving VXA-CoV2-1, which showed demonstrable CD8 T-cell responses. While it was able to generate relatively impressive immune responses, the company's pill didn't produce high levels of neutralizing antibodies in trial participants, which diverges from what we've seen following traditional COVID-19 injections.</p>\n<p>Though Vaxart may have a promising pathway to treat norovirus, it has a steep hill to climb if it's to become relevant in the COVID-19 treatment space. It's probably a bit early to pass judgment either way, but Rahimi's price target is potentially a bit too aggressive for a clinical-stage drug developer.</p>\n<h2>Columbia Care: Implied upside of 180%</h2>\n<p>Wall Street is also exceptionally bullish on the U.S. cannabis industry, with most multistate operators expected to fly. But one marijuana stock with particularly high upside, according to the high-water price target on Wall Street of more than $15 a share, is <b>Columbia Care</b> (OTC:CCHWF). If Wall Street's most aggressive price target comes to fruition, Columbia Care's shareholders could be reveling in a 180% gain over the coming 12 months.</p>\n<p>Columbia Care finds itself perfectly set up to take advantage of a rapidly growing cannabis market in the U.S. In total, 36 states have waved the green flag on medical weed, with half of those states legalizing consumption and/or adult-use sales. With Columbia Care primarily focused on serving medical pot customers for years, it was a pretty seamless transition to also servicing a larger pool of recreational weed clients.</p>\n<p>Although the company is generating healthy growth from its existing dispensaries -- 60% same-store sales growth in the first quarter from retail locations open in Q1 2020 -- its core strategy has involved making strategic acquisitions. Last month, the company closed a $240 million deal to acquire Green Leaf Medical, which added operational and in-development dispensaries in four states, as well as close to 400,000 square feet of cultivation and production capacity.</p>\n<p>Additionally, the purchase of The Green Solution in September 2020 stood out, as it allowed Columbia Care to gobble up Colorado's largest vertically integrated cannabis operator. Colorado sports the second-highest annual weed sales in the U.S., behind only California.</p>\n<p>The last thing to take note of is Columbia Care's focus on limited-license markets. States like Pennsylvania and Ohio cap the number of retail licenses they'll issue, as well as how many licenses a single business can hold. Meanwhile, Virginia assigns licenses by jurisdiction. The point is this: Columbia Care will be able to establish a presence in key markets without being overrun by competition.</p>\n<p>To be clear, I believe Columbia Care has a very bright future. However, expecting a 180% climb in 12 months might be a bit much.</p>\n<h2>Inovio Pharmaceuticals: Implied upside of 329%</h2>\n<p>But the crème de la crème of upside opportunity, at least on this list, belongs to clinical-stage biotech stock <b>Inovio Pharmaceuticals</b> (NASDAQ:INO). According to Oppenheimer analyst Hartaj Singh, Inovio has a price target of $35, implying that it'll more than quadruple in value over the next year.</p>\n<p>The bulk of Singh's thesis rests with INO-4800, the company's experimental COVID-19 vaccine candidate. Since Inovio's vaccines are DNA-based, Singh believes they can be modified easily to tackle new variants of the disease as they arise. Further, Singh points out that INO-4800 has a more stable shelf life than some of the more popular COVID-19 vaccines. For context, Inovio reported on May 10 that its mid-stage study involving INO-4800 was well-tolerated, with T cell immune responses observed in all age groups.</p>\n<p>Inovio also has a relatively large pipeline for a company with a sub-$2 billion market cap. It has nearly a dozen different DNA-based candidates in clinical trials at the moment to treat everything from infectious diseases to cancer. Generally speaking, the more swings a drug developer gets to take, the more likely they are to hit a home run.</p>\n<p>On the other hand, Inovio Pharmaceuticals has struck out swinging for more than four decades. This is to say that Inovio has yet to bring an approved product to market since its inception more than 40 years ago.</p>\n<p>What's more, INO-4800 wasn't exactly getting the red carpet treatment in the lucrative U.S. market. The U.S. Food and Drug Administration placed a partial clinical hold on Inovio's phase 2/3 trial to gather more info on INO-4800 and its delivery device, known as Cellectra. Months later, the U.S. government pulled funding for a late-stage trial of INO-4800, coercing the company to look internationally to conduct its large-scale study.</p>\n<p>In other words, with a long history of disappointment in its wake, Inovio is the type of stock investors should avoid until it actually shows us the goods.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-15 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药","VXRT":"Vaxart, Inc"},"source_url":"https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151526974","content_text":"Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S. and global economy bode well for the growth stocks that have led the market higher.\nBut growth isn't the only category analysts believe will outperform. Small-cap stocks -- companies with market caps ranging from $300 million to as high as $2 billion -- were absolutely pummeled during the coronavirus crash and now appear set to thrive. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await.\nVaxart: Implied upside of 158%\nThe first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock Vaxart (NASDAQ:VXRT). A little over a month ago, analyst Yasmeen Rahimi at Piper Sander placed an $18 price target and an overweight rating on Vaxart. Based on its $6.99 closing price on July 12, we're talking about roughly 158% in implied upside over the next year.\nFor Rahimi, the selling point on Vaxart is the company's Vector-Adjuvant-Antigen Standardized Technology, or VAAST platform. This proprietary oral vaccine platform is deemed relatively low risk by Rahimi given the amount of clinical data readily available. Specifically, VAAST is designed to activate systemic and mucosal immunity in the nose, lungs, intestines, and mouth to help fight against airborne viruses, such as influenza and norovirus.\nBut it's not norovirus that's put Vaxart on the map in 2021. That honor goes to VXA-CoV2-1, the company's clinical-stage coronavirus disease 2019 (COVID-19) candidate. Vaxart's experimental treatment is unique in that it's a pill, not an injection. A pill would likely result in higher vaccination rates, and it would certainly be easier from a distribution and administration standpoint.\nBack on May 3, Vaxart released data from its phase 1 study involving VXA-CoV2-1, which showed demonstrable CD8 T-cell responses. While it was able to generate relatively impressive immune responses, the company's pill didn't produce high levels of neutralizing antibodies in trial participants, which diverges from what we've seen following traditional COVID-19 injections.\nThough Vaxart may have a promising pathway to treat norovirus, it has a steep hill to climb if it's to become relevant in the COVID-19 treatment space. It's probably a bit early to pass judgment either way, but Rahimi's price target is potentially a bit too aggressive for a clinical-stage drug developer.\nColumbia Care: Implied upside of 180%\nWall Street is also exceptionally bullish on the U.S. cannabis industry, with most multistate operators expected to fly. But one marijuana stock with particularly high upside, according to the high-water price target on Wall Street of more than $15 a share, is Columbia Care (OTC:CCHWF). If Wall Street's most aggressive price target comes to fruition, Columbia Care's shareholders could be reveling in a 180% gain over the coming 12 months.\nColumbia Care finds itself perfectly set up to take advantage of a rapidly growing cannabis market in the U.S. In total, 36 states have waved the green flag on medical weed, with half of those states legalizing consumption and/or adult-use sales. With Columbia Care primarily focused on serving medical pot customers for years, it was a pretty seamless transition to also servicing a larger pool of recreational weed clients.\nAlthough the company is generating healthy growth from its existing dispensaries -- 60% same-store sales growth in the first quarter from retail locations open in Q1 2020 -- its core strategy has involved making strategic acquisitions. Last month, the company closed a $240 million deal to acquire Green Leaf Medical, which added operational and in-development dispensaries in four states, as well as close to 400,000 square feet of cultivation and production capacity.\nAdditionally, the purchase of The Green Solution in September 2020 stood out, as it allowed Columbia Care to gobble up Colorado's largest vertically integrated cannabis operator. Colorado sports the second-highest annual weed sales in the U.S., behind only California.\nThe last thing to take note of is Columbia Care's focus on limited-license markets. States like Pennsylvania and Ohio cap the number of retail licenses they'll issue, as well as how many licenses a single business can hold. Meanwhile, Virginia assigns licenses by jurisdiction. The point is this: Columbia Care will be able to establish a presence in key markets without being overrun by competition.\nTo be clear, I believe Columbia Care has a very bright future. However, expecting a 180% climb in 12 months might be a bit much.\nInovio Pharmaceuticals: Implied upside of 329%\nBut the crème de la crème of upside opportunity, at least on this list, belongs to clinical-stage biotech stock Inovio Pharmaceuticals (NASDAQ:INO). According to Oppenheimer analyst Hartaj Singh, Inovio has a price target of $35, implying that it'll more than quadruple in value over the next year.\nThe bulk of Singh's thesis rests with INO-4800, the company's experimental COVID-19 vaccine candidate. Since Inovio's vaccines are DNA-based, Singh believes they can be modified easily to tackle new variants of the disease as they arise. Further, Singh points out that INO-4800 has a more stable shelf life than some of the more popular COVID-19 vaccines. For context, Inovio reported on May 10 that its mid-stage study involving INO-4800 was well-tolerated, with T cell immune responses observed in all age groups.\nInovio also has a relatively large pipeline for a company with a sub-$2 billion market cap. It has nearly a dozen different DNA-based candidates in clinical trials at the moment to treat everything from infectious diseases to cancer. Generally speaking, the more swings a drug developer gets to take, the more likely they are to hit a home run.\nOn the other hand, Inovio Pharmaceuticals has struck out swinging for more than four decades. This is to say that Inovio has yet to bring an approved product to market since its inception more than 40 years ago.\nWhat's more, INO-4800 wasn't exactly getting the red carpet treatment in the lucrative U.S. market. The U.S. Food and Drug Administration placed a partial clinical hold on Inovio's phase 2/3 trial to gather more info on INO-4800 and its delivery device, known as Cellectra. Months later, the U.S. government pulled funding for a late-stage trial of INO-4800, coercing the company to look internationally to conduct its large-scale study.\nIn other words, with a long history of disappointment in its wake, Inovio is the type of stock investors should avoid until it actually shows us the goods.","news_type":1},"isVote":1,"tweetType":1,"viewCount":51,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":189336952,"gmtCreate":1623244700176,"gmtModify":1631894034514,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"$ACTCProterra going to merge~https://www.google.com/amp/s/seekingalpha.com/amp/article/4432196-actc-a-very-popular-spac-soon-holds-a-vote-on-buying-proterra","listText":"$ACTCProterra going to merge~https://www.google.com/amp/s/seekingalpha.com/amp/article/4432196-actc-a-very-popular-spac-soon-holds-a-vote-on-buying-proterra","text":"$ACTCProterra going to merge~https://www.google.com/amp/s/seekingalpha.com/amp/article/4432196-actc-a-very-popular-spac-soon-holds-a-vote-on-buying-proterra","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/189336952","isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":852736071,"gmtCreate":1635301474432,"gmtModify":1635301508927,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FVRR\">$Fiverr International Ltd.(FVRR)$</a>hais","listText":"<a href=\"https://laohu8.com/S/FVRR\">$Fiverr International Ltd.(FVRR)$</a>hais","text":"$Fiverr International Ltd.(FVRR)$hais","images":[{"img":"https://static.tigerbbs.com/fbf74a8f4d8721100dbe1d28d827cf26","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/852736071","isVote":1,"tweetType":1,"viewCount":1508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":158610714,"gmtCreate":1625147415938,"gmtModify":1631890295695,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Oh dear","listText":"Oh dear","text":"Oh dear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158610714","repostId":"1106960651","repostType":4,"repost":{"id":"1106960651","pubTimestamp":1625147164,"share":"https://www.laohu8.com/m/news/1106960651?lang=&edition=full","pubTime":"2021-07-01 21:46","market":"us","language":"en","title":"Barclays says ZipRecruiter’s stock price can jump 20% amid U.S. labor supply and demand mismatch","url":"https://stock-news.laohu8.com/highlight/detail?id=1106960651","media":"CNBC","summary":"Barclays initiated coverage of ZipRecruiter on Thursday, saying the online recruiting platform is we","content":"<div>\n<p>Barclays initiated coverage of ZipRecruiter on Thursday, saying the online recruiting platform is well-positioned to gain as U.S. employers face challenges filling job openings.\n“ZIP is differentiated...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/01/barclays-says-ziprecruiter-stock-price-can-jump-20percent.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Barclays says ZipRecruiter’s stock price can jump 20% amid U.S. labor supply and demand mismatch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBarclays says ZipRecruiter’s stock price can jump 20% amid U.S. labor supply and demand mismatch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-01 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/01/barclays-says-ziprecruiter-stock-price-can-jump-20percent.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Barclays initiated coverage of ZipRecruiter on Thursday, saying the online recruiting platform is well-positioned to gain as U.S. employers face challenges filling job openings.\n“ZIP is differentiated...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/01/barclays-says-ziprecruiter-stock-price-can-jump-20percent.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZIP":"ZipRecruiter Inc."},"source_url":"https://www.cnbc.com/2021/07/01/barclays-says-ziprecruiter-stock-price-can-jump-20percent.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1106960651","content_text":"Barclays initiated coverage of ZipRecruiter on Thursday, saying the online recruiting platform is well-positioned to gain as U.S. employers face challenges filling job openings.\n“ZIP is differentiated from online peers (as well as traditional internal⁄third-party recruiting services) by its AI-based matching, resulting in faster⁄better quality candidate recommendations and faster time-to-hire, alleviating key pain points for employer-customers,” Barclays’ Trevor Young said in a note released Thursday.\nThe firm gave ZipRecruiter an overweight rating and set its 12-month price target at $30, implying upside of 20%.\nBarclays’ call comes as the labor market remains in focus, with U.S. employers citing worker shortages and difficulty replacing lost jobs from the pandemic.\nAs job openings outpace job seeker demand, Barclays says the current employment trend “sets up favorable dynamics” for ZipRecruiter.\n“We believe more and more employers will explore additional resources, such as ZipRecruiter, to try to source candidates that are willing and able to work,” Young said.\nBarclays lauded ZipRecruiter’s strong technological capabilities and brand awareness among employers as differentiators from peer job marketplaces.\nWith work-from-home continuing, the firm said greater geographic mobility should keep demand for online recruiting tools high in the near future.\nZipRecruiter debuted on the New York Stock Exchange in May. The stock price closed at $24.98 on Wednesday and gained 8.4% in June.","news_type":1},"isVote":1,"tweetType":1,"viewCount":26,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162089031,"gmtCreate":1624027515923,"gmtModify":1631885865572,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>i thought should be factored in. Not new thing that apple wanna do their own chips","listText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>i thought should be factored in. Not new thing that apple wanna do their own chips","text":"$Intel(INTC)$i thought should be factored in. Not new thing that apple wanna do their own chips","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/162089031","isVote":1,"tweetType":1,"viewCount":196,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140244522,"gmtCreate":1625664427066,"gmtModify":1631890295646,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Comment like and comment like and comment","listText":"Comment like and comment like and comment","text":"Comment like and comment like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/140244522","repostId":"1156748810","repostType":4,"isVote":1,"tweetType":1,"viewCount":75,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140242664,"gmtCreate":1625664286458,"gmtModify":1631890295660,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Nice nice nice, posting for tiger coins","listText":"Nice nice nice, posting for tiger coins","text":"Nice nice nice, posting for tiger coins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/140242664","repostId":"2149390140","repostType":4,"isVote":1,"tweetType":1,"viewCount":18,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128743796,"gmtCreate":1624534065915,"gmtModify":1631894034439,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128743796","repostId":"1187819280","repostType":4,"repost":{"id":"1187819280","pubTimestamp":1624529642,"share":"https://www.laohu8.com/m/news/1187819280?lang=&edition=full","pubTime":"2021-06-24 18:14","market":"us","language":"en","title":"The ‘shelter in suburbia’ trade is about to reverse — and these stocks will suffer","url":"https://stock-news.laohu8.com/highlight/detail?id=1187819280","media":"MarketWatch","summary":"5 reasons the pandemic megatrend is over.\n\nOne of the biggest investment stories of the COVID-19 pan","content":"<blockquote>\n <b>5 reasons the pandemic megatrend is over.</b>\n</blockquote>\n<p>One of the biggest investment stories of the COVID-19 pandemic has been the boom in consumer discretionary stocks with a “shelter in suburbia” theme. From e-commerce platforms to home improvement stores to furniture and housewares merchants, many of the top performers have fit this flavor.</p>\n<p>Take the broad-based Vanguard Consumer Discretionary Index Fund ETF VCR, +0.66% that surged more than 90% from March 2020 to March 2021. That was thanks to components like home improvement stocks Lowe’s LOW, -0.30% and Home Depot HD, -0.33% alongside retailers like TJX TJX, -0.08%.</p>\n<p>Lately, however, performance has started to lag for many of these names. In fact, since April 1 we’ve seen these three stocks all drift slightly into the red even as the S&amp;P 500 SPX, -0.11% has tacked on about 6% in the same period.</p>\n<p>And some fear that may only be the beginning. As one Wall Street insider said recently in a Bloomberg interview, a “huge unwind” is coming for stay-at-home stocks, including hardware stores and home-goods merchants.</p>\n<p>While some big-name “suburbia” trades are still relatively stable, signs of trouble are already emerging at the fringes. Century Communities CCS, -0.34% and Dream Finders Homes DFH, -2.55%, two mid-tier single family homebuilders, have seen shares crash by double digits over the last month. On the furnishings side, appliance giant Whirlpool Corporation WHR, -0.51% and department store Nordstrom JWN, +2.03% are down sharply from their spring highs.</p>\n<p><b>Here are five big reasons why:</b></p>\n<p><b>1.</b>&nbsp;<b>The upgrade cycle is over</b></p>\n<p>Last summer, white-collar workers who were stuck at home made note of overdue projects and took advantage of being able to easily meet with contractors. But in many ways, this growth is not sustainable.</p>\n<p>Consider the kind of purchases homeowners were making according to data from the NPD Group. Faucets, kitchen cabinets and even toilets were among the most popular products sold in 2020. Needless to say, even the most profligate homeowners aren’t going to follow this upgrade cycle of remodeling kitchens and bathrooms on an annual basis.</p>\n<p>The same is true for furniture and other home goods. Internet giant Comscore recorded the highest visitation to related websites in history in May 2020 with 133 million web surfers shopping for some kind of home goods. Once again, a new couch or lamp is not an annual purchase — so this trend seems unsustainable for much longer.</p>\n<p><b>2.&nbsp;Valuations are stretched</b></p>\n<p>Speaking of post-pandemic peaks for home-goods purveyors, we’ve seen the financials bear out these big increases via boosted profits and sales. However, we’ve also seen the stock of many related merchants surge even more — stretching their valuations from historical norms.</p>\n<p>Take TJX. Currently this discount retailer has a forward price-to-earnings ratio of more than 26, compared with a forward P/E of just 21 in spring 2020. Its trailing price-to-sales ratio is now 2.1 compared with 1.4.</p>\n<p>What’s more, valuations for previous darlings like TJX are out of line with peers, too. Consider the forward P/E of the overall S&amp;P 500 index is 22 right now, and other similar names like Macy’s M, +0.70% and Big Lots BIG, -3.71% actually have forward P/E ratios well under 10. You can argue TJX is unique, of course… but you also may want to be aware of what “fair value” looks like for many other stocks outside fashionable stay-at-home trades right now.</p>\n<p><b>3.&nbsp;Delays and shortages</b></p>\n<p>Future growth from pandemic-fueled peaks in these stocks is not impossible, of course. But given supply chain disruptions it seems highly unlikely. There are a host of reasons for these delays, including overseas shipping delays as well as capacity and output crunches that are affecting many industries, but “stay at home” stocks seem particularly hard hit.</p>\n<p>Home improvement products are simply nowhere to be found, with roughly 94% of builders reporting “at least some serious shortages of appliances” according to the National Association of Home Builders. Another 93% are running short on framing lumber and 87% say it is hard to obtain windows and doors.</p>\n<p>Even if you can get past demand concerns, without the raw materials to get to work it’s very hard to see future growth in this category.</p>\n<p><b>4.&nbsp;Inflationary pressures</b></p>\n<p>For the people who haven’t already ponied up the cash for a contractor or made their peace with extended delays for their expensive new furniture, there is a pretty big disincentive right now for new shoppers: inflation.</p>\n<p>The cost of living as measured by the Consumer Price Index jumped 0.6% in May to run at a 5% annual rate. That was not only higher than expectations, but the fastest pace since the summer of 2008. The inflation risks were so pronounced that the Federal Reserve publicly stated it could move up the schedule for expected interest rate increases to keep the risks under wraps.</p>\n<p>Inflation isn’t always a death knell, of course. But it has historically eroded purchasing power and could curtail some of the spending in “stay at home” stocks that we’ve seen in the last year or so.</p>\n<p><b>5.&nbsp;Home-equity hubris</b></p>\n<p>Speaking of red-hot inflation: In May, the median price for U.S. homes topped $350,000 for the first time ever — up 23.6% from 2020. What’s more, a Realtor.com survey showed roughly a third of selling homeowners expect to get more than their asking price, and roughly the same amount expect an offer within a week of listing.</p>\n<p>Some of this is justifiable. Many articles have been written in recent years about the dearth of supply in attractive markets, and it’s important to acknowledge the remote work of the pandemic has indeed created some disruptive introspection into why people live where they do.</p>\n<p>But here’s where things get dicey: homeowners who have already spent the expected premium on their home’s price well in advance. According to Freddie Mac, about $152.7 billion in equity loans were taken out on U.S. houses last year, a massive increase of 41.7% from 2019 and the highest refinancing cash-out dollar amount since 2007.</p>\n<p>Anyone remember what happened to the real-estate market in 2007? Or the similar sense of seller entitlement from those days? There’s no clear signs of a bubble bursting just yet, but there’s real risk American homeowners may be overly optimistic about what their homes are worth — and a chance this home equity loan free-for-all simply isn’t sustainable for much longer.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The ‘shelter in suburbia’ trade is about to reverse — and these stocks will suffer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe ‘shelter in suburbia’ trade is about to reverse — and these stocks will suffer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 18:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/the-shelter-in-suburbia-trade-is-about-to-reverse-and-these-stocks-will-suffer-11624457411?siteid=yhoof2><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5 reasons the pandemic megatrend is over.\n\nOne of the biggest investment stories of the COVID-19 pandemic has been the boom in consumer discretionary stocks with a “shelter in suburbia” theme. From e-...</p>\n\n<a href=\"https://www.marketwatch.com/story/the-shelter-in-suburbia-trade-is-about-to-reverse-and-these-stocks-will-suffer-11624457411?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/the-shelter-in-suburbia-trade-is-about-to-reverse-and-these-stocks-will-suffer-11624457411?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187819280","content_text":"5 reasons the pandemic megatrend is over.\n\nOne of the biggest investment stories of the COVID-19 pandemic has been the boom in consumer discretionary stocks with a “shelter in suburbia” theme. From e-commerce platforms to home improvement stores to furniture and housewares merchants, many of the top performers have fit this flavor.\nTake the broad-based Vanguard Consumer Discretionary Index Fund ETF VCR, +0.66% that surged more than 90% from March 2020 to March 2021. That was thanks to components like home improvement stocks Lowe’s LOW, -0.30% and Home Depot HD, -0.33% alongside retailers like TJX TJX, -0.08%.\nLately, however, performance has started to lag for many of these names. In fact, since April 1 we’ve seen these three stocks all drift slightly into the red even as the S&P 500 SPX, -0.11% has tacked on about 6% in the same period.\nAnd some fear that may only be the beginning. As one Wall Street insider said recently in a Bloomberg interview, a “huge unwind” is coming for stay-at-home stocks, including hardware stores and home-goods merchants.\nWhile some big-name “suburbia” trades are still relatively stable, signs of trouble are already emerging at the fringes. Century Communities CCS, -0.34% and Dream Finders Homes DFH, -2.55%, two mid-tier single family homebuilders, have seen shares crash by double digits over the last month. On the furnishings side, appliance giant Whirlpool Corporation WHR, -0.51% and department store Nordstrom JWN, +2.03% are down sharply from their spring highs.\nHere are five big reasons why:\n1. The upgrade cycle is over\nLast summer, white-collar workers who were stuck at home made note of overdue projects and took advantage of being able to easily meet with contractors. But in many ways, this growth is not sustainable.\nConsider the kind of purchases homeowners were making according to data from the NPD Group. Faucets, kitchen cabinets and even toilets were among the most popular products sold in 2020. Needless to say, even the most profligate homeowners aren’t going to follow this upgrade cycle of remodeling kitchens and bathrooms on an annual basis.\nThe same is true for furniture and other home goods. Internet giant Comscore recorded the highest visitation to related websites in history in May 2020 with 133 million web surfers shopping for some kind of home goods. Once again, a new couch or lamp is not an annual purchase — so this trend seems unsustainable for much longer.\n2. Valuations are stretched\nSpeaking of post-pandemic peaks for home-goods purveyors, we’ve seen the financials bear out these big increases via boosted profits and sales. However, we’ve also seen the stock of many related merchants surge even more — stretching their valuations from historical norms.\nTake TJX. Currently this discount retailer has a forward price-to-earnings ratio of more than 26, compared with a forward P/E of just 21 in spring 2020. Its trailing price-to-sales ratio is now 2.1 compared with 1.4.\nWhat’s more, valuations for previous darlings like TJX are out of line with peers, too. Consider the forward P/E of the overall S&P 500 index is 22 right now, and other similar names like Macy’s M, +0.70% and Big Lots BIG, -3.71% actually have forward P/E ratios well under 10. You can argue TJX is unique, of course… but you also may want to be aware of what “fair value” looks like for many other stocks outside fashionable stay-at-home trades right now.\n3. Delays and shortages\nFuture growth from pandemic-fueled peaks in these stocks is not impossible, of course. But given supply chain disruptions it seems highly unlikely. There are a host of reasons for these delays, including overseas shipping delays as well as capacity and output crunches that are affecting many industries, but “stay at home” stocks seem particularly hard hit.\nHome improvement products are simply nowhere to be found, with roughly 94% of builders reporting “at least some serious shortages of appliances” according to the National Association of Home Builders. Another 93% are running short on framing lumber and 87% say it is hard to obtain windows and doors.\nEven if you can get past demand concerns, without the raw materials to get to work it’s very hard to see future growth in this category.\n4. Inflationary pressures\nFor the people who haven’t already ponied up the cash for a contractor or made their peace with extended delays for their expensive new furniture, there is a pretty big disincentive right now for new shoppers: inflation.\nThe cost of living as measured by the Consumer Price Index jumped 0.6% in May to run at a 5% annual rate. That was not only higher than expectations, but the fastest pace since the summer of 2008. The inflation risks were so pronounced that the Federal Reserve publicly stated it could move up the schedule for expected interest rate increases to keep the risks under wraps.\nInflation isn’t always a death knell, of course. But it has historically eroded purchasing power and could curtail some of the spending in “stay at home” stocks that we’ve seen in the last year or so.\n5. Home-equity hubris\nSpeaking of red-hot inflation: In May, the median price for U.S. homes topped $350,000 for the first time ever — up 23.6% from 2020. What’s more, a Realtor.com survey showed roughly a third of selling homeowners expect to get more than their asking price, and roughly the same amount expect an offer within a week of listing.\nSome of this is justifiable. Many articles have been written in recent years about the dearth of supply in attractive markets, and it’s important to acknowledge the remote work of the pandemic has indeed created some disruptive introspection into why people live where they do.\nBut here’s where things get dicey: homeowners who have already spent the expected premium on their home’s price well in advance. According to Freddie Mac, about $152.7 billion in equity loans were taken out on U.S. houses last year, a massive increase of 41.7% from 2019 and the highest refinancing cash-out dollar amount since 2007.\nAnyone remember what happened to the real-estate market in 2007? Or the similar sense of seller entitlement from those days? There’s no clear signs of a bubble bursting just yet, but there’s real risk American homeowners may be overly optimistic about what their homes are worth — and a chance this home equity loan free-for-all simply isn’t sustainable for much longer.","news_type":1},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140246581,"gmtCreate":1625664236543,"gmtModify":1631890295671,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Nice nice nice nice nice. Tiger coins nice.","listText":"Nice nice nice nice nice. Tiger coins nice.","text":"Nice nice nice nice nice. Tiger coins nice.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/140246581","repostId":"2149160390","repostType":4,"isVote":1,"tweetType":1,"viewCount":264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126951939,"gmtCreate":1624542881321,"gmtModify":1631894034426,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>zzzz pls up","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>zzzz pls up","text":"$Tiger Brokers(TIGR)$zzzz pls up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126951939","isVote":1,"tweetType":1,"viewCount":9,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183622186,"gmtCreate":1623329726945,"gmtModify":1631894034505,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Proterra to the moon","listText":"Proterra to the moon","text":"Proterra to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/183622186","isVote":1,"tweetType":1,"viewCount":339,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160308161,"gmtCreate":1623771182053,"gmtModify":1631886774685,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PTRA\">$ArcLight Clean Transition Corp(PTRA)$</a>rubbish sia so weak, dump this shit","listText":"<a href=\"https://laohu8.com/S/PTRA\">$ArcLight Clean Transition Corp(PTRA)$</a>rubbish sia so weak, dump this shit","text":"$ArcLight Clean Transition Corp(PTRA)$rubbish sia so weak, dump this shit","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/160308161","isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":830390036,"gmtCreate":1629007465625,"gmtModify":1631890295587,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"PROTERRA","listText":"PROTERRA","text":"PROTERRA","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/830390036","repostId":"1138531277","repostType":4,"isVote":1,"tweetType":1,"viewCount":163,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143211379,"gmtCreate":1625795647391,"gmtModify":1631890295638,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Nice Man","listText":"Nice Man","text":"Nice Man","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143211379","repostId":"1153646457","repostType":4,"isVote":1,"tweetType":1,"viewCount":9,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120865520,"gmtCreate":1624319216660,"gmtModify":1631894034479,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/120865520","repostId":"2145031705","repostType":4,"isVote":1,"tweetType":1,"viewCount":73,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169725391,"gmtCreate":1623851621113,"gmtModify":1631885865616,"author":{"id":"3566283048885824","authorId":"3566283048885824","authorIdStr":"3566283048885824","name":"ThomasSim","avatar":"https://static.tigerbbs.com/5ae8ed8301f80085926169333185d321","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566283048885824"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>whats holding you back intel","listText":"<a href=\"https://laohu8.com/S/INTC\">$Intel(INTC)$</a>whats holding you back intel","text":"$Intel(INTC)$whats holding you back intel","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169725391","isVote":1,"tweetType":1,"viewCount":66,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}